


## AMENDMENTS TO THE CLAIMS

1 (Previously Presented). A compound of the Formula I



Formula I

wherein:

R1 is NHR10, (substituted or unsubstituted C<sub>1</sub>-C<sub>6</sub>alkyl)NHR10 or (unsubstituted or substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl)NHR10;

R10 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>1</sub>-C<sub>6</sub>alkyl(OH), C<sub>1</sub>-C<sub>6</sub>alkylidenyl(OH)R11, or an amino protecting group;

R11 is C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)C<sub>1</sub>-C<sub>6</sub>alkyl, C(O)O-C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R2 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl;

R4 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, or C<sub>2</sub>-C<sub>6</sub>alkenyl;

R5 is hydrogen, aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, hydroxy, C<sub>1</sub>-C<sub>6</sub>alkoxy, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl;

R6 and R7 are independently hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted C<sub>2</sub>-C<sub>6</sub>alkenyl, or R6 and R7 together with the carbon atom to which they are attached form a carbocyclic ring of up to 8 atoms which is optionally partly unsaturated or a substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl group which is optionally partly unsaturated;

R8 is hydrogen, unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkyl, unsubstituted or substituted aryl, unsubstituted or substituted (C<sub>1</sub>-C<sub>6</sub>alkyl)C<sub>3</sub>-C<sub>8</sub>cycloalkyl, or unsubstituted or substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl;

Q is -S(O)<sub>2</sub>- or -C(O)-;


m is a number selected from 1 or 2;

R3 is substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>3</sub>-C<sub>8</sub> cycloalkyl, substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl, or aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group; and R9 is hydrogen, C<sub>1</sub>-C<sub>6</sub>alkyl, C<sub>2</sub>-C<sub>6</sub>alkenyl, C<sub>2</sub>-C<sub>6</sub>alkynyl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, C<sub>3</sub>-

C<sub>8</sub>cycloalkenyl, cyano, optionally substituted aryl, optionally substituted -O-aryl, optionally substituted -N-aryl, optionally substituted -S-aryl, -aryl-aryl(K1)(K2), -O-aryl-aryl(K1)(K2), -N-aryl-aryl(K1)(K2), -S-aryl-aryl(K1)(K2), -O-C<sub>1</sub>-C<sub>6</sub>alkyl, or C<sub>1</sub>-C<sub>6</sub>alkylaryl, wherein K1 is halo or -CF<sub>3</sub>, and K2 is hydrogen, halo or -CF<sub>3</sub> or K1 and K2 together form a methylenedioxy group; or

R3 is optionally substituted aryl, C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, C<sub>3</sub>-C<sub>8</sub>cycloalkyl, (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; and R9 is aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -O-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, -N-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group, or -S-aryl substituted by at least one -SO<sub>2</sub>CF<sub>3</sub> group; or a pharmaceutically acceptable salt thereof.

2 (Previously Presented). A compound according to claim 1 having Formula II



Formula II

wherein

R1, R2, R3, R5, R6, R7, R8, R9 and Q are as defined in claim 1 or a pharmaceutically acceptable salt thereof.

3 (Previously Presented). A compound according to claim 2 wherein R3 is selected from substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl, substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl, or substituted (C<sub>1</sub>-C<sub>6</sub> alkyl) C<sub>3</sub>-C<sub>8</sub> cycloalkyl; or a pharmaceutically acceptable salt or solvate thereof.

4 (Previously Presented). A compound according to claim 3 wherein the substituted C<sub>1</sub>-C<sub>6</sub>alkylaryl or substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkylaryl group contains an aryl moiety selected from phenyl, thiazolyl, pyridyl, naphthyl, thienyl, oxazolyl, isoxazolyl and indolyl which is substituted by from one to three groups independently selected from C<sub>1</sub>-C<sub>6</sub> alkyl, -OC<sub>1</sub>-C<sub>6</sub> alkyl, -OCF<sub>3</sub>, amide, aryl, aryloxy, SO<sub>2</sub>(C<sub>1-6</sub> alkyl), SO<sub>2</sub>CF<sub>3</sub>, NHamide, carboxamide, sulfonamide, Nhsulfonamide, imide,

hydroxy, carboxy, nitro, halo, tri(chloro or fluoro)methyl, and cyano; or a pharmaceutically acceptable salt thereof.

5 (Previously Presented). A compound according to claim 2 wherein R3 is a substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group or a substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl aryl group wherein:


the C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub> alkylaryl group is methyl, ethyl or propyl;

the C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl moiety within the substituted C<sub>1</sub>-C<sub>6</sub>alkyl(O)-C<sub>1</sub>-C<sub>6</sub>alkyl aryl group is a moiety of formula -CH<sub>2</sub>OCH<sub>2</sub>-;

the substituted aryl moiety is 2-fluorophenyl, 3-fluorophenyl, 4-fluorophenyl, 2,3-difluorophenyl, 2,4-difluorophenyl, 2,5-difluorophenyl, 2,6-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,4,6-trifluorophenyl, 2,3,4-trifluorophenyl, 2,4,5-trifluorophenyl, 2,3,6-trifluorophenyl, 2,3,5-trifluorophenyl, 2-chlorophenyl, 3-chlorophenyl, 4-chlorophenyl, 2,6-dichlorophenyl, 2,3-dichlorophenyl, 2,4-dichlorophenyl, 2,5-dichlorophenyl, 2-chloro-4-fluorophenyl, 2-methylphenyl, 2,6-difluoro-3-methylphenyl, 3,6-difluoro-2-chlorophenyl, 2-fluoro-6-chlorophenyl, 2-fluoro-3-chlorophenyl, 2-fluoro-4-chlorophenyl, 2,6-difluoro-3-chlorophenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 2-trifluoromethylphenyl, 2-fluoro-5-trifluoromethylphenyl, 2-fluoro-3-trifluoromethylphenyl, 2-fluoro-6-trifluoromethylphenyl, 2-chloro-3-trifluoromethylphenyl, 4-trifluoromethoxyphenyl, 3-trifluoromethoxyphenyl, 2-trifluoromethoxyphenyl, 2-cyanophenyl, 3-cyanophenyl, 4-cyanophenyl, 4-methanesulphonylphenyl, or 2-methyl thiazolyl;


or a pharmaceutically acceptable salt or solvate thereof.

6 (Previously Presented). A compound according to claim 2 wherein R1 is



or a pharmaceutically acceptable salt or solvate thereof.

7 (Previously Presented). A compound according to claim 2 wherein R1 is selected from  $-\text{C}(\text{CH}_2\text{F})_2\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{F})(\text{CH}_2\text{CH}_2\text{F})\text{NH}_2$ ,  $-\text{C}(\text{CF}_3)(\text{CH}_3)\text{NH}_2$ ,  $-\text{C}(\text{CH}_2\text{CH}_2\text{F})_2\text{NH}_2$ ,



8 (Previously Presented). A compound according to claim 2 wherein R6 and R7 are each  $\text{C}_1$ - $\text{C}_3$  alkyl or form a five or six membered carbocyclic ring; or R6 and R7 are independently  $\text{C}_1$ - $\text{C}_6$ alkyl or  $\text{C}_2$ - $\text{C}_6$ alkenyl, in which one or both groups are substituted by one, two, or three halo atoms; or R6 is hydrogen and R7 is  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_2$ - $\text{C}_6$ alkenyl which is substituted by one, two, or three halo atoms; or R6 and R7 together with the carbon atom to which they are attached may form a  $\text{C}_3$ - $\text{C}_8$ cycloalkyl group which is optionally partly unsaturated and which is substituted by one, two, or three halo atoms; or a pharmaceutically acceptable salt thereof.

9 (Previously Presented). A compound according to claim 1 wherein R4 is hydrogen or methyl, or a pharmaceutically acceptable salt or solvate thereof.

10 (Previously Presented). A compound according to claim 2 wherein R5 is hydrogen,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $\text{C}_1$ - $\text{C}_6$ alkoxy,  $\text{C}_1$ - $\text{C}_6$ alkyl which is substituted by hydroxy or  $\text{C}_1$ - $\text{C}_6$ alkyl which is substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

11 (Previously Presented). A compound according to claim 10 wherein R5 is hydrogen, methyl, ethyl, propyl or n-propyl, or a pharmaceutically acceptable salt thereof.

12 (Previously Presented). A compound according to claim 2 wherein R8 is hydrogen,  $\text{C}_1$ - $\text{C}_6$ alkyl,  $(\text{C}_1$ - $\text{C}_6$ alkyl) $\text{C}_3$ - $\text{C}_8$ cycloalkyl, benzyl, 1-phenylethyl,  $\text{C}_1$ - $\text{C}_6$ alkyl which is substituted by hydroxy, methoxy,  $\text{CONH}_2$ , or  $\text{CON}(\text{CH}_3)_2$ , or  $\text{C}_1$ - $\text{C}_6$ alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.

13 (Previously Presented). A compound according to claim 12 wherein R8 is C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by hydroxy or C<sub>1</sub>-C<sub>6</sub>alkyl which is substituted by one, two, or three halo atoms, phenyl substituted by one, two, or three halo atoms or benzyl substituted by one, two, or three halo atoms, or a pharmaceutically acceptable salt thereof.


14 (Previously Presented). A compound according to claim 2 wherein R9 is selected from the group consisting of unsubstituted or substituted thienyl, unsubstituted or substituted naphthyl, unsubstituted or substituted phenoxy and unsubstituted or substituted phenyl; wherein the substituents when present are each independently selected from the group consisting of halo, methyl, ethyl, propyl, t-butyl, trifluoromethyl, trifluoromethoxy, methoxy, ethoxy, cyano, methylsulphonyl, phenyl, phenoxy, thienyl, pyridyl, thiazolyl, oxazolyl, nitro, CONH<sub>2</sub>, furanyl, benzothiophenyl and benzofuranyl; or a pharmaceutically acceptable salt thereof.

15 (Previously Presented). A compound according to claim 14 wherein R9 is selected from phenyl, 4-methylsulphonylphenyl, 3-methylsulphonylphenyl, 4-fluorophenyl, 2-fluorophenyl, 3-fluorophenyl, 3-chlorophenyl, 2-chlorophenyl, 4-chlorophenyl, 4-t-butylphenyl, 4-trifluoromethylphenyl, 3-trifluoromethylphenyl, 4-nitrophenyl, 3-nitrophenyl, 4-bromophenyl, 3-bromophenyl, 2-bromophenyl, 4-methylphenyl, 3-methylphenyl, 4-phenylphenyl, 3-phenylphenyl, 4-phenoxyphenyl, 3-phenoxyphenyl, 4-cyanophenyl, 3-cyanophenyl, 4-carbamoylphenyl, 4-methoxyphenyl, 3-methoxyphenyl, thienyl, thiazolyl, pyridyl, phenoxy, 4-chlorophenoxy, 2,3-dichlorophenyl, 3,4-dichlorophenyl, naphthyl, oxazolyl, 2,4-difluorophenyl, 3,4-difluorophenyl, 3,5-difluorophenyl, 2,3-difluorophenyl, 2,6-difluorophenyl, 2,5-difluorophenyl, 2-fluoro-3-chlorophenyl, 4-ethylphenyl, 4-ethoxyphenyl, 3,4,5-trifluorophenyl, 3-fluoro-4-chlorophenyl and 4-carbamoylphenyl; or a pharmaceutically acceptable salt thereof.


16 (Previously Presented). A pharmaceutical formulation comprising one or more compounds according to claim 1 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable diluents or carriers therefor.

17 (Previously Presented). A pharmaceutical formulation according to claim 16 wherein the formulation further comprises one or more growth hormone secretagogue compounds and/or a bone-antiresorptive agent.

18 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula XI or XIb




with a compound of formula XIII




wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in claim 1.

19 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising deprotecting a compound of Formula



wherein R2, R3, R4, R5, R6, R7, R8, R9, m and Q are as defined in claim 1, and PG is an amino protecting group.

20 (Previously Presented). A process for producing a compound of Formula I as defined in claim 1 comprising coupling a compound of Formula




with a compound of formula XIV



wherein R1, R2, R3, R4, R5, R6, R7, R8, R9 and Q are as defined in claim 1.

21-23(Canceled).

24 (Previously Presented). A compound having the formula



wherein:

X is O, Y is 4-Cl, Z is 2-F and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 3-F and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 4-F and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2,3-F<sub>2</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2,5-F<sub>2</sub> and R5 is Et;  
or  
X is CH<sub>2</sub>, Y is 4-Cl, Z is 2,6-F<sub>2</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2,6-F<sub>2</sub> and R5 is Et;  
or  
X is CH<sub>2</sub>, Y is 4-Cl, Z is 3,5-F<sub>2</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2,4,6-F<sub>3</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2,3,5-F<sub>3</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2,6-Cl<sub>2</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2-F-6-Cl and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2-Cl-3,6-F<sub>2</sub> and R5 is Et;  
or  
X is O, Y is 4-Cl, Z is 2-CN and R5 is Et;  
or a pharmaceutically acceptable salt thereof.

25 (Previously Presented). 2-(R)-2-(2-Amino-2-methylpropionylamino)-3-(2,6-difluoro-3-methylphenyl)methoxy propionic acid N-[5-(4-chlorophenyl)-3,3-dimethyl-1,1-dioxo-2,3-dihydroisothiazol-4-ylmethyl]-N-ethylamide; or a pharmaceutically acceptable salt thereof.